LY2444296

$80$1,100

Products Details

Product Description

– LY2444296 is an orally bioavailable, high-affinity and selective short-acting kappa opioid receptor (KOPR) antagonist, with a Ki value of ∼1 nM. LY2444296 exhibits anti-anxiety like effects[1][2].

Web ID

– HY-135230

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Neuroscience-Neuromodulation

Molecular Formula

– C24H22F2N2O2

References

– [1]Huang P, et al. Two short-acting kappa opioid receptor antagonists (zyklophin and LY2444296) exhibited different behavioral effects from the long-acting antagonist norbinaltorphimine in mouse anxiety tests. Neurosci Lett. 2016 Feb 26;615:15-20.|[2]Valenza M, et al. “Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats”. Psychopharmacology (Berl). 2017 Aug;234(15):2219-2231.

CAS Number

– 1346133-11-6

Molecular Weight

– 408.44

Compound Purity

– 99.59

SMILES

– O=C(N)C1=CC=C(OC2=CC=C(CN3[C@H](C4=CC=CC(F)=C4)CCC3)C=C2)C(F)=C1

Clinical Information

– No Development Reported

Research Area

– Neurological Disease

Solubility

– Ethanol : 27.5 mg/mL (ultrasonic)

Target

– Opioid Receptor

Isoform

– κ Opioid Receptor/KOR

Pathway

– GPCR/G Protein;Neuronal Signaling

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=